The North America Thyroid Function Test Market is witnessing substantial growth driven by rising awareness regarding thyroid disorders, increasing adoption of advanced diagnostic technologies, and a surge in the prevalence of thyroid-related diseases. The market was valued at USD 1,030 Million in 2025 and is projected to reach USD 2,040 Million by 2035, growing at a CAGR of 6.6% from 2024 to 2035.
The economic impact of tariffs on "North America Thyroid Function Test Market".
Market Growth Drivers
Rising Prevalence of Thyroid Disorders: The increasing occurrence of thyroid-related conditions such as hypothyroidism, hyperthyroidism, and thyroid cancer are driving demand for thyroid function tests across North America. According to Abbott Laboratories, the growing awareness and early screening programs in the United States have led to a higher volume of diagnostic procedures, boosting the market growth for thyroid testing.
Advancements in Diagnostic Technologies: Companies such as Thermo Fisher Scientific are investing heavily in the research and development of innovative and highly sensitive diagnostic kits and assays, enabling earlier and more accurate detection of thyroid disorders. Automated platforms, high-throughput analyzers, and point-of-care testing solutions are streamlining workflows in laboratories and clinics, making thyroid function tests more accessible and efficient.
Market Trends
Growing Preference for At-Home and Point-of-Care Testing: With the advent of telemedicine and remote diagnostics, companies like Everlywell are offering at-home thyroid function test kits that provide patients with the convenience and privacy they seek. This trend is expected to widen the consumer base and promote regular monitoring of thyroid health without frequent hospital visits.
Integration of AI & Digital Health Platforms: The adoption of artificial intelligence (AI) in interpreting thyroid test results and the use of digital health records by companies such as Quest Diagnostics enable healthcare practitioners to deliver personalized therapy. Enhanced data analytics and integrated platforms help in tracking patient outcomes and improving the accuracy of diagnosis, further fueling market growth.
Market Opportunity
Expansion into Underserved Rural Areas: Major diagnostic companies like LabCorp have the opportunity to further penetrate untapped rural regions in North America by setting up mobile diagnostic units and collaborating with local clinics. This expands access to thyroid function tests among populations with limited healthcare infrastructure.
Development of Multiplex Assays: The evolution towards multiplexed testing, spearheaded by companies like Siemens Healthineers, represents an opportunity for market players to develop and market kits capable of evaluating multiple thyroid markers in a single test, thereby improving diagnostic efficiency and patient outcomes.
North America Thyroid Function Test Market Revenue (USD Million), 2020-2035
The chart illustrates the projected growth trajectory of the North America Thyroid Function Test Market from 2020 to 2035. The market demonstrates a steady upward trend, propelled by technological advancements, rising patient awareness, and broader screening programs. From USD 760 Million in 2020, the market is anticipated to reach USD 2,040 Million by 2035, reflecting a CAGR of 6.6%. Notably, accelerated adoption of novel diagnostic kits and point-of-care solutions post-2024 boosts market performance, with significant jumps observed in 2028 and beyond. This indicates the market's robust and resilient expansion amid evolving healthcare demands.
North America Thyroid Function Test Market by Regions Share (%), 2025
In 2025, the United States dominates the North America Thyroid Function Test Market with a commanding 78% share, attributed to its advanced healthcare infrastructure and the presence of major diagnostic companies. Canada follows with 14%, supported by universal healthcare policies and growing awareness programs. Mexico holds a 6% market share as the country's diagnostic sector develops. The remaining 2% is divided between the Rest of North America (including territories and Caribbean nations), indicating untapped opportunities. This regional distribution underscores the importance of developed healthcare markets in driving overall growth, while highlighting future prospects for expansion in less penetrated areas.
Recent Developments
In April 2024, Abbott Laboratories launched a next-generation multiplex thyroid function assay in the United States, designed to simultaneously detect TSH, FT4, and FT3 with higher sensitivity and improved turnaround time. The new solution aims to reduce diagnostic delays and support clinical decision-making in primary care settings.
In March 2024, LabCorp announced a partnership with a leading telehealth provider to integrate at-home thyroid function testing with virtual consultation services. This collaboration is designed to meet the growing demand for remote diagnostic solutions and streamline patient care for thyroid health, especially among rural populations.
In February 2024, Quest Diagnostics revealed the development of an AI-powered diagnostic platform specifically tailored to thyroid panel analytics. The platform enhances laboratory workflow efficiency, delivers robust clinical insights, and aids physicians in recommending personalized thyroid disease management paths for their patients.
Press Releases